Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 juin 2025 05h00 HE | Source: TOLREMO Therapeutics

TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors

- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with...
01 avr. 2022 08h30 HE | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting

Two poster presentations highlight Phase 1 data for LP352 in healthy volunteers SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage...
08 sept. 2021 07h00 HE | Source: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin Company...